Abstracts tagged "livedo reticularis"

Abstract Number: 0949 • ACR Convergence 2021
Single-Cell RNA Sequencing of APS Skin Reveals Endothelial Pathology and Cellular Interactions
Hui Shi¹, Allison Billi², Rachael Wasikowski¹, Claire Hoy³, Kelsey Gockman¹, Lam Tsoi¹, Johann Gudjonsson², Pei-Suen Tsou¹ and Jason Knight¹, ¹University of Michigan, Ann Arbor, MI, ²Department of Dermatology, University of Michigan, Ann Arbor, MI, ³University of Michigan, Ann Arbor
Background/Purpose: Although antiphospholipid syndrome (APS) regularly presents with discrete thrombotic events, many patients will also acquire organ damage over time secondary to occlusive neointimal formation…
Abstract Number: 2182 • 2015 ACR/ARHP Annual Meeting
Increased Risk of Livedo Reticularis Associated with Antiphospholipid Antibodies in Patients with Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis
Ersilia M. DeFilippis¹, Denis Wahl² and Stephane Zuily², ¹Department of Medicine, Brigham and Women's Hospital, Boston, MA, ²CHU de Nancy, Vascular Medicine Division and Regional Competence Center For Rare Vascular And Systemic Autoimmune Diseases, Nancy, F-54000, France; Inserm, UMR_S 1116, Nancy, F-54000, France; Université de Lorraine, Nancy, F-54000, France, Nancy, France
Background/Purpose : Livedo reticularis (LR) is present in patients with systemic lupus erythematosus (SLE), and the role of antiphospholipid antibodies (aPL) is controversial. Therefore our…
Abstract Number: 2642 • 2013 ACR/ARHP Annual Meeting
A Novel Genetic Basis For Systemic Vasculitis: Polyarteritis Nodosa Caused By Recessive Mutations In An Immune-Related Gene
Reeval Segel^1,2, Pnina Elkan-Navon³, Sarah B. Pierce⁴, Tom Walsh⁴, Judith Barash⁵, Shay Padeh⁶, Avraham Zlotogorski⁷, Yackov Berkun⁸, Isabel Voth⁹, Philip Hashkes¹⁰, Liora Harel¹¹, Eduard Ling¹², Fatos Yalcinkaya¹³, Ozgur Kasapcopur¹⁴, Paul F. Renbaum¹⁵, Ariella Weinberg-Shukron¹⁵, Barbara Schormair¹⁶, Mordechai Shohat¹⁷, Alan A. Rubinow¹⁸, Elon Pras¹⁹, Juliane Winkelmann²⁰, Mustafa Tekin²¹, Yair Anikster²², Mary-Claire King⁴ and Ephrat Levy-Lahad¹⁵, ¹Medical Genetics and Pediatrics, Shaare Zedek Medical Center, Jerusalem, Israel, ²Hebrew University Medical School, Jerusalem, Israel, ³Pediatrics, Shaare Zedek Medical Center, Jerusalem, Israel, ⁴Medical Genetics, University of Washington, Seattle, WA, ⁵Pediatric Day Care, Kaplan Medical Center, Rehovot, Israel, ⁶Pediatrics, Sheba Medical Center, Ramat Gan, Israel, ⁷Department of Dermatology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel, ⁸Pediatrics, Hadassah Medical Center, Mount Scopus, Jerusalem, Israel, ⁹Department of Neurology, Technische Universitat Munchen Klinikum rechts der Isar, Munich, Germany, ¹⁰Pediatric Rheumatology, Shaare Zedek Medical Center, Jerusalem, Israel, ¹¹Pediatric Rheumatology unit, Schneider Children's Medical Center, Tel Aviv University, Petach Tikvah, Israel, ¹²Rheumatology Unit, Soroka University Medical Center and Ben-Gurion University, Beer-Sheva, Beer Sheva, Israel, ¹³Pediatric Nephrology and Rheumatology, Ankara University, Ankara, Turkey, ¹⁴Ankara University, Ankara, Turkey, ¹⁵Medical Genetics, Shaare Zedek Medical Center, Jerusalem, Israel, ¹⁶Helmholtz Zentrum Munchen, Munich, Germany, ¹⁷Rafael Recanati medical genetics Institute, Rabin Medical Center, Beilinson Hospital, Petach Tikvah, Israel, ¹⁸Hadassah Medical Center, Jerusalem, Israel, ¹⁹Institute of Human Genetics, Sheba Medical Center, Ramat Gan, Israel, ²⁰Genetics, Stanford University, San Francisco, CA, ²¹Dr. John T. Macdonald Foundation Department of Human Genetics and John P. Hussman Institute for Human Genomics, Miller School of Medicine, University of Miami, Miami, FL, ²²Metabolic Disease Unit, Sheba Medical Center, Ramat Gan, Israel
Background/Purpose: Polyarteritis nodosa (PAN) is a systemic necrotizing vasculitis. Disease pathogenesis and possible genetic factors are poorly understood. We identified familial, mostly pediatric PAN, in…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].